Takeshi Hashimoto1, Krishnan Rahul2, Toshikazu Takeda3, Nicole Benfante3, John P Mulhall2, Hedvig Hricak4, James A Eastham3, Hebert Alberto Vargas5. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Tokyo Medical University, Tokyo, Japan. 2. Sexual and Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer, New York, NY. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: vargasah@mskcc.org.
Abstract
OBJECTIVE: To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. METHODS: We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. RESULTS: After TRT, there was a significant increase in serum testosterone (516.5ng/dl vs. 203.0ng/dl), PSA (4.2ng/ml vs. 3.3ng/ml), and prostate volume (55.2cm3 vs. 39.4cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). CONCLUSIONS: After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy. Copyright Â
OBJECTIVE: To investigate the multiparametric prostate magnetic resonance imaging (mpMRI) findings in patients treated with testosterone replacement therapy (TRT) while on active surveillance for low-risk prostate cancer. METHODS: We retrospectively reviewed 12 patients who underwent mpMRI before and after TRT while on active surveillance. Changes in serum testosterone level, prostate-specific antigen (PSA), prostate biopsy findings, prostate volume, and Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) score before and after TRT were summarized. RESULTS: After TRT, there was a significant increase in serum testosterone (516.5ng/dl vs. 203.0ng/dl), PSA (4.2ng/ml vs. 3.3ng/ml), and prostate volume (55.2cm3 vs. 39.4cm3). In total, 2 patients had biopsy progression during the study period. The PI-RADSv2 scores before and after TRT were unchanged in 10/12 patients; none of these demonstrated biopsy progression on post-TRT. The PI-RADSv2 scores increased after TRT in 2/12 patients; both showed Gleason score upgrade on follow-up biopsy. Of these 2 patients, 1 patient underwent radical treatment due to clinical progression. The area under the curve for detecting biopsy progression calculated from PI-RADSv2 score after TRT was 0.90, which was better than that calculated from post-TRT PSA level (0.48). CONCLUSIONS: After TRT, mpMRI findings remained stable in patients without biopsy progression, whereas PI-RADSv2 score increase was identified in patients with Gleason score upgrade on follow-up biopsy. Copyright Â
Authors: Stephen Overholser; Matthew Nielsen; Kathleen Torkko; Daniel Cwilka; Brandi Weaver; Xiaoyu Shi; Robin J Leach; Javier Hernandez; Tim Huang; Ian M Thompson; Ian M Thompson Journal: J Urol Date: 2015-01-28 Impact factor: 7.450
Authors: Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis Journal: Radiology Date: 2016-04-01 Impact factor: 11.105
Authors: Abraham Morgentaler; Janet A Benesh; Bela S Denes; Natalia Kan-Dobrosky; Diala Harb; Michael G Miller Journal: J Sex Med Date: 2014-08-18 Impact factor: 3.802
Authors: Caroline M A Hoeks; Diederik M Somford; Inge M van Oort; Henk Vergunst; Jorg R Oddens; Geert A Smits; Monique J Roobol; Meelan Bul; Thomas Hambrock; J Alfred Witjes; Jurgen J Fütterer; Christina A Hulsbergen-van de Kaa; Jelle O Barentsz Journal: Invest Radiol Date: 2014-03 Impact factor: 6.016
Authors: D Nörenberg; O Solyanik; B Schlenker; G Magistro; B Ertl-Wagner; D A Clevert; C Stief; M F Reiser; M D'Anastasi Journal: Urologe A Date: 2017-05 Impact factor: 0.639